CSChin-Cheng Su

Chin-Cheng Su

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chin-Cheng Su has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Dar-Ren Chen

    Comprehensive Breast Cancer Center, Changhua Christian Hospital, Changhua 50006, Taiwan, R.O.C.

    4 shared publications
  • Shou-Jen Kuo

    Comprehensive Breast Cancer Center, Changhua Christian Hospital, Changhua 50006, Taiwan, R.O.C.

    4 shared publications
  • Su-Yu Chien

    Department of Pharmacy, Changhua Christian Hospital, Changhua 500‑06, Taiwan, R.O.C.

    3 shared publications
  • Tsung-Lang Chiu

    Division of Neurooncology, Neuro‑Medical Scientific Center, Buddhist Tzu‑Chi General Hospital, Hualien 97004, Taiwan, R.O.C.

    3 shared publications
  • Chun-Yuan Cheng

    Department of Surgery, Changhua Christian Hospital, Changhua 500-06

    2 shared publications
  • Yi-Hsiang Lin

    Division of General Surgery Tzu Chi University 970 Hualien Taiwan, R.O.C

    2 shared publications

Latest Publications

  • Open Access

    Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways

    by Chin‑Cheng Su

    Tanshinone IIA (Tan‑IIA; C19H18O3) is derived from Danshen (the roots of Salvia miltiorrhiza), and has been reported to possess anti‑inflammatory and antioxidant activities. Tan‑IIA can inhibit BxPC‑3 human pancreatic cancer cells in vitro through inducing endoplasmic reticulum stress and apoptosis via mitochondrial pathways. However, the efficacy and molecular mechanisms of Tan‑IIA in human pancreatic cancer have not yet been elucidated. The transmembrane tyrosine kinases, including insulin‑like growth factor 1 receptor (IGF1R), vascular endothelial growth factor receptor (VEGFR) or epidermal growth factor receptor (EGFR) have been implicated in the survival and metastasis of cancer. In addition, the Ras/Raf/mitogen‑activated protein kinase kinase (MEK)/extracellular signal‑regulated kinase (ERK) and phosphoinositide 3‑kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathways are the most commonly dysregulated kinase cascades in human cancer. The present study aimed to investigate the efficacy and molecular mechanisms of Tan‑IIA in MiaPaCa‑2 human pancreatic carcinoma cells. The protein expression levels of EGFR, IGF1R, VEGFR, Ras, PI3K, AKT, mTOR, Raf, MEK, ERK and phosphatase and tensin homolog (PTEN) were detected in Tan‑IIA‑treated MiaPaCa‑2 cells by western blotting. The results demonstrated that the protein expression levels of EGFR, IGF1R, VEGFR, Ras, Raf, MEK, ERK, PI3K, AKT, mTOR and PTEN were decreased in MiaPaCa‑2 cells treated with various concentrations of Tan‑IIA for different durations. In conclusion, these findings indicated that Tan‑IIA may inhibit MiaPaCa‑2 human pancreatic cancer cells; the molecular mechanisms underlying this inhibitory effect may be involved in downregulating EGFR, IGF1R and VEGFR expression, and dual blockade of the Ras/Raf/MERK/ERK and PI3K/AKT/mTOR pathways.


  • Tanshinone IIA inhibits gastric carcinoma AGS cells by decreasing the protein expression of VEGFR and blocking Ras/Raf/MEK/ERK pathway

    by Chin-Cheng Su

    The RAS/RAF/MEK/ERK pathway is one of the most frequently dysregulated kinase cascades in human cancer, that facilitate the proliferation and survival of cancers driven by growth factor receptors. Tanshinone IIA (Tan-IIA) was extracted from Danshen (Salviae Miltiorrhizae Radix). Tan-IIA inhibition of the proliferation of gastric cancer are well documented, but the molecular mechanisms of Tan-IIA inhibition of gastric cancer have not been well elucidated. We evaluated the protein expression of vascular epidermal growth factor receptor (VEGFR), human epidermal growth factor receptor 2 (HER2), Ras, Raf, MEK, ERK, PARP, caspase-3 and β-actin in AGS cells by western blotting. The results showed that AGS cells treated with Tan-IIA upregulated the protein expression of PARP and caspase-3 but decreased VEGFR, HER2, Ras, Raf, MEK and ERK time- and dose-dependently. These findings demonstrated that Tan-IIA inhibited human gastric cancer AGS cells; one of the molecular mechanisms may be through decreasing the protein expression of VEGFR and HER2, then blocking the Ras/Raf/MEK/ERK pathway to induce the activation of PARP and caspase-3 to induce apoptosis.


  • Open Access

    Effect of Lipodox in combination with bevacizumab in a patient with a metastatic malignant phyllodes breast tumor: A case report

    by Chin Cheng Su, Chih‑Jung Chen, Shou‑Jen Kuo

    A 76‑year‑old female patient with a malignant phyllodes tumor underwent modified radical mastectomy and wide excision. Multiple nodules were observed in the operated wound area. Positron emission tomography‑computed tomography (PET‑CT) revealed recurrent disease in the left breast, the adjacent left third rib, the left internal mammary region and the left ilium. A novel formulation of bevacizumab (5 mg/m2, first day) in combination with liposomal doxorubicin (Lipodox, 30 mg/m2, second day) was administered for 3 cycles every 2 weeks, and subsequently wide excision was performed. Lipodox (40 mg/m2) was administered for 3 cycles every 3 weeks, starting 4 weeks after the surgery. Follow‑up whole body PET‑CT scanning, 3 and 6 months later, indicated no sign of residual hypermetabolic malignancy. Malignant phyllodes tumors do not usually respond to chemotherapy or radiotherapy. In the present case report, a novel formulation of bevacizumab in combination with Lipodox was administered as neoadjuvant chemotherapy in a patient with a malignant phyllodes tumor and preoperative tumor shrinkage was achieved, resulting in clear resection margins.


  • Open Access

    Tanshinone IIA increases protein expression levels of PERK, ATF6, IRE1α, CHOP, caspase-3 and caspase-12 in pancreatic cancer BxPC-3 cell-derived xenograft tumors

    by Tsung-Lang Chiu, Chin Cheng Su

    Tanshinone (Tan)-IIA is a derivative of phenanthrenequinone and the main active ingredient isolated from Salviae miltiorrhizae radix (Danshen). Previous studies have demonstrated that Tan‑IIA increased the protein expressions levels of protein kinase RNA‑like endoplasmic reticulum kinase (PERK), activating transcription factor (ATF) 6, caspase‑12 and CCAAT‑enhancer‑binding protein homologous protein (CHOP), to induce endoplasmic reticulum (ER) stress and apoptosis in human pancreatic cancer BxPC‑3 cells. However, to the best of our knowledge, the effects of Tan‑IIA on pancreatic cancer cells have not been investigated in vivo. Further studies are required to elucidate the therapeutic potential of Tan‑IIA in inducing ER stress in cancer cells in vivo. The present study aimed to investigate the effects of Tan‑IIA on the expression of ER stress‑related proteins in BxPC‑3‑derived xenograft tumors. A total of 30 male severe combined immunodeficiency mice (age, 4 weeks) were implanted with BxPC‑3 cells (2x106/0.2 ml) and subsequently treated with various doses of Tan‑IIA (0, 30 and 90 mg/kg) for 4 weeks. After mice were sacrificed on day 33, the xenograft tumors were dissected and total protein was extracted for western blot analysis. The results of the present study demonstrated that Tan‑IIA inhibited the growth of BxPC‑3‑derived xenograft tumors. In addition, Tan‑IIA increased the protein expression levels of PERK, ATF6, caspase‑12, inositol‑requiring enzyme (IRE) 1α, eukaryotic initiation factor (eIF) 2α, phosphorylated (p)‑c‑Jun N‑terminal kinase (JNK), CHOP and caspase‑3 in a dose‑dependent manner. These results indicated that Tan‑IIA induced ER stress via increasing the protein expression levels of PERK, ATF6, caspase‑12, IRE1α, eIF2α, p‑JNK, CHOP and caspase‑3 in BxPC‑3 cells in vivo. Therefore, it may be hypothesized that Tan‑IIA has potential for the development of novel therapeutic strategies for the treatment of patients with pancreatic cancer.


  • Open Access

    Myoid hamartoma of the breast with focal chondromyoxid metaplasia and pseudoangiomatous stromal hyperplasia: A case report

    by Chin-Cheng Su, Chih-Jung Chen, Shou-Jen Kuo, Dar-Ren Chen

    Hamartomas of the breast, also known as fibroadenolipomas, lipofibroadenomas or adenolipomas, are benign lesions. Hamartomas account for between 0.04 and 1.15% of all benign breast tumors in females. Myoid hamartoma of the breast (MHB) is extremely rare. The present study describes a case of MHB in a 44‑year‑old female. Screening mammography revealed a lobulated partial indistinct isodense mass measuring ~3.8 cm in the upper outer quadrant of the left breast. Sonographic examinations revealed a 2‑3‑cm mass in the left breast, which was fairly well circumbscribed and demonstrated complex scattered echogenic areas and isoechoic tissue. A core needle biopsy demonstrated fibrocystic changes, with small focal ductule aggregations. As malignancy could not be excluded, a partial mastectomy was performed using a circumareolar incision. The mass was histopathologically diagnosed as MHB with focal chondromyoxid metaplasia and pseudoangiomatous stromal hyperplasia. The histological diagnosis was based upon the findings of the well‑circumscribed tumor, which was composed of entrapped mammary ducts, fat cells and myoid stromal components, with focal chondromyxoid metaplasia and pseudoangiomatous stromal hyperplasia. The tumor cells exhibited diffuse cluster of differentiation 34‑positive immunoreactivity, which was consistent with a diagnosis of pseudoangiomatous stromal hyperplasia.


  • Sann-Joong-Kuey-Jian-Tang decreases the protein expression of mammalian target of rapamycin but increases microtubule associated protein II light chain 3 expression to inhibit human BxPC-3 pancreatic carcinoma cells

    by Chin-Cheng Su

    Sann‑Joong‑Kuey‑Jian‑Tang (SJKJT), a Traditional Chinese Medicinal prescription, has been used for the treatment of lymphadenopathy and solid tumors, and has shown therapeutic potential in a number of human malignant tumor cell lines, such as Hep‑G2 hepatocellular carcinoma cells. Previous mechanistic studies demonstrated that SJKJT inhibited the proliferation of BxPC‑3 pancreatic carcinoma cells through the extrinsic and intrinsic apoptotic pathways in vitro. SJKJT was also shown to be cytotoxic to colo 205 colon cancer cells by inducing autophagy in vitro. The present study therefore investigated molecular mechanisms of autophagy in human BxPC‑3 pancreatic cancer cells treated with SJKJT. The cytotoxic effects of SJKJT on BxPC‑3 human pancreatic carcinoma cells were evaluated using an MTT assay. Furthermore, the expression of autophagy‑associated proteins, including mammalian target of rapamycin (mTOR), beclin‑1, autophagocytosis‑associated protein (Atg)3, Atg7, Atg5‑Atg12 and microtubule‑associated protein II light chain 3 (LC3‑II), was assessed using western blot analysis. The results demonstrated that BxPC‑3 cells treated with SJKJT exhibited decreased expression levels of mTOR and increased expression of LC3‑II protein. In addition, the expression of the beclin‑1, Atg3, Atg7 and Atg5‑Atg12 proteins was increased during the first 24 h, but decreased from 48 to 72 h. The results showed that SJKJT inhibited the proliferation of human BxPC‑3 pancreatic cancer cells in vitro. A possible underlying molecular mechanism may be the induction of autophagy. Further investigation into the therapeutic potential of SJKJT in human pancreatic cancer is required.


  • Open Access

    Tanshinone IIA inhibits the growth of pancreatic cancer BxPC-3 cells by decreasing protein expression of TCTP, MCL-1 and Bcl-xL

    by Cheng-Yen Huang, Tsung-Lang Chiu, Shou-Jen Kuo, Su-Yu Chien, Dar-Ren Chen, Chin-Cheng Su

    Pancreatic cancer remains a challenging disease worldwide. Tanshinone IIA (Tan‑IIA) is one of the active constituents of Danshen (Radix Salviae miltiorrhizae). Tan‑IIA has been hypothesized to inhibit numerous human cancer cells by various molecular mechanisms. However, the efficacy and molecular mechanism of Tan‑IIA action in pancreatic cancer has not been well studied. In the present study, the cytotoxicity of Tan‑IIA in human pancreatic cancer BxPC‑3 cells was evaluated by MTT assay. Cell cycle analysis of BxPC‑3 cells treated with Tan‑IIA was performed by flow cytometry (FACS). Protein expression levels of TCTP, Mcl‑1, Bcl‑xL, Bax and Caspase‑3 in BxPC‑3 cells were measured by western blot analysis. The results revealed that Tan‑IIA inhibited BxPC‑3 cells in a time‑ and dose‑dependent manner. FACS analysis demonstrated that Tan‑IIA increases the rate of sub‑G1 phase. BxPC‑3 cells treated with Tan‑IIA were identified to upregulate protein expression of Bax and Caspase‑3 and downregulate expression of TCTP, Mcl‑1 and Bcl‑xL. These results indicate that Tan‑IIA may inhibit BxPC‑3 human pancreatic cancer cells through the induction of apoptosis by decreasing protein expression of TCTP, Mcl‑1 and Bcl‑xL and increasing Bax expression in vitro. The chemotherapeutic potential of Tan‑IIA for human pancreatic cancer warrants further study.


  • Open Access

    The treatment of glioblastoma multiforme through activation of microglia and TRAIL induced by rAAV2-mediated IL-12 in a syngeneic rat model

    by Tsung-Lang Chiu, Mei-Jan Wang, Chin-Cheng Su

    Background: Microglial cells are the predominant immune cells in malignant brain tumors, but tumors may release some factors to reduce their defensive functions. Restoration of the anti-cancer function of microglia has been proposed as a treatment modality for glioblastoma. We examined the effect of intra-cranially administered recombinant adeno-associated virus encoding interleukin-12 (rAAV2/IL12) on transfection efficiency, local immune activity and survival in a rat model of glioblastoma multiforme. Methods: F344 rats were injected with rAAV2/IL12 and implanted with syngeneic RG2 cells (glioblastoma cell line). Intracerebral interleukin-12 and interferon-γ concentrations were determined by ELISA. Activation of microglia was determined by expressions of ED1 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) which were evaluated by Western blotting and immunohistochemistry. The proliferation of cancer cells was evaluated with Ki67 immunohistochemistry and apoptosis of cancer cells with TUNEL. Results: The brains treated with rAAV2/IL-12 maintained high expression of interleukin-12 and interferon-γ for at least two months. In syngeneic tumor model, brains treated with rAAV2/IL12 exhibited more infiltration of activated microglia cells as examined by ED1 and TRAIL stains in the tumor. In addition, the volume of tumor was markedly smaller in AAV2/IL12-treated group and the survival time was significantly longer in this group too. Conclusion: The intra-cerebrally administered rAAV2/IL-12 efficiently induces long lasting expression of IL-12, the greater infiltration of activated microglia cells in the tumor associated improved immune reactions, resulting in the inhibited growth of implanted glioblastoma and the increased survival time of these rats.


  • Open Access

    Tanshinone IIA inhibits BT-20 human breast cancer cell proliferation through increasing caspase 12, GADD153 and phospho-p38 protein expression

    by Chin-Cheng Su, Meng-Yi Yan, Su-Yu Chien, Shou-Jen Kuo, Dar-Ren Chen

    Breast cancer is the leading cause of cancer-related deaths in women worldwide. Tanshinone IIA (Tan-IIA) is one of the pure compounds from Salviae miltiorrhizae radix (Danshen). Tan-IIA can inhibit human breast cancer cells but the molecular mechanisms are not well understood. Our previous study showed that Tan-IIA can inhibit hep-J5 human hepatocellular carcinoma cells through the endoplasmic reticulum (ER) stress-induced apoptotic pathway. In the present study, we evaluated the effects of Tan-IIA on BT-20 human breast cancer cells and assessed the involvement of the ER-stress-apoptotic pathway. The cytotoxicity of Tan-IIA in BT-20 cells was measured by the MTT assay. The cell cycles were analyzed by flow cytometry. The expression of ER stress-related proteins in BT-20 cells treated with Tan-IIA were evaluated by western blotting and immunocytochemical staining. These results showed that Tan-IIA can inhibit BT-20 cells and increase the sub-G1 phase in a time- and dose-dependent manner. Tan-IIA could increase the protein expression of caspase 12, GADD153, caspase 3, phospho-JNK, phospho-p38 and Bax, but decreased Bcl-xl and phospho-ERK expression in BT-20 cells. These findings indicate that Tan-IIA possesses therapeutic potential for human breast cancer BT-20 cells; one of the molecular mechanisms may be through inducing ER stress and the MAPK pathway to induce apoptosis and inhibit proliferation.


  • Open Access

    Tanshinone IIA inhibits human breast cancer MDA-MB-231 cells by decreasing LC3-II, Erb-B2 and NF-κBp65

    by Chin-Cheng Su, Su-Yu Chien, Shou-Jen Kuo, Yao-Li Chen, Chun-Yuan Cheng, Dar-Ren Chen

    The ability of tanshinone IIA (Tan-IIA) to inhibit the proliferation of human breast cancer cell lines in vitro and in vivo is well documented. However, the molecular mechanisms have not been fully elucidated. In the present study, MDA-MB-231 cells were treated with different concentrations of Tan-IIA for 48 h, followed by protein extraction for western blotting. For an in vivo study, MDA-MB-231 cells were implanted directly into female SCID mice which were divided randomly into three groups to be treated with vehicle, Tan-IIA (20 mg/kg) and Tan-IIA (60 mg/kg) every other day orally, with treatment starting 4 weeks after inoculation with the MDA-MB-231 cells. The results showed that Tan-IIA inhibited the proliferation of MDA-MB-231 cells and decreased the protein expression of LC3-II and Erb-B2 in vitro. Treatment with Tan-IIA (20 or 60 mg/kg) for 90 days resulted in a reduction in tumor size and weight compared to the control group. The protein expression of NF-κBp65 was reduced, while caspase-3 was up-regulated compared to the control group. These findings indicate that Tan-IIA inhibits tumor growth in a MDA-MB-231 xenograft animal model. One of the molecular mechanisms may be through a decrease in NF-κBp65 and an increase in caspase-3 expression.